Analysis of U.S. Patent 3,428,735: Scope, Claims, and Patent Landscape

What does U.S. Patent 3,428,735 cover?

U.S. Patent 3,428,735, issued to Eli Lilly and Company on February 18, 1969, claims the chemical compound benzodiazepine derivative specifically identified as diazepam. The patent's primary focus is the chemical composition, synthesis methods, and therapeutic applications related to diazepam.

What are the core claims of Patent 3,428,735?

Main claims

The patent contains 11 claims, with the most critical being:

Claim 1: A compound of the formula 1,4-benzodiazepine-2-one with specified substitutions forming diazepam. It describes the chemical structure emphasizing the benzodiazepine core with various substituents, specifically a 2-chlorophenyl, 2,6-dichlorophenyl, or similar groups.
Claims 2-11: Dependent claims specify particular substitutions, synthesis methods, and formulations. These include methods of preparing diazepam, such as cyclization reactions, and specific salts and derivatives.

Scope of claims

The claims broadly cover:

The chemical compound diazepam as a benzodiazepine derivative.
Synthetic methods to produce the compound.
Pharmaceutical formulations containing diazepam.

Claims do not extend to other benzodiazepines with different substitutions unless explicitly claimed, restricting the patent to diazepam and similar structurally related derivatives.

What is the scope of the patent?

The patent scope is centered on:

Chemical structure: Benzodiazepine core with phenyl substituents.
Synthesis: Specific chemical processes for producing diazepam.
Pharmaceutical Use: Treatment of anxiety, muscle spasms, seizures, as disclosed in the patent description.

The patent does not cover:

Other benzodiazepines (e.g., lorazepam, alprazolam) with different side groups.
Non-chemical methods of treatment.
Delivery devices or formulations beyond what is presented.

Legal scope effectively protects diazepam's chemical structure and synthesis route, as understood from early patent texts in this class.

How does Patent 3,428,735 fit within the patent landscape?

Overlapping patents

Later benzodiazepine patents: Patents like U.S. Patent 4,096,157 (1978) broadened benzodiazepine derivatives' scope.
Method of use patents: Many later patents focus specifically on therapeutic methods, not chemical compounds.
Formulation patents: Focus on specific delivery systems for benzodiazepines.

Patent family and extensions

The patent has no direct family members but was foundational for Eli Lilly’s benzodiazepine portfolio.
It became prior art against later patents claiming similar compounds.

Patent expiration and patent landscape

Due to its 1969 issue date, the patent expired in 1986 (patent term of 17 years from grant for utility patents at the time).
The expiration opened the market for generic production of diazepam.

Litigation and licensing

The patent was not notably litigated, as original claims covered compounds already in clinical use upon issuance.
No significant licensing disputes are documented.

Patent landscape analysis summary

Aspect	Details
Patent family status	Single patent, expired
Overlapping patents	Later benzodiazepine patents, method patents
Market impact	Enabled generic diazepam post-expiry
Litigation history	None significant

Key points from patent claims and landscape

The patent established the chemical and synthesis basis for diazepam.
It has a narrow scope focused on a specific benzodiazepine compound.
Its expiration facilitated generic access.
The patent landscape includes numerous subsequent benzodiazepine developments, often building on the chemical class established by this patent.

Key Takeaways

U.S. Patent 3,428,735 covers diazepam's chemical structure and synthesis methods, with claims limited primarily to the specific benzodiazepine compound.
The patent's scope does not extend to other benzodiazepines with different substitution patterns.
Its expiration in 1986 led to broad generic manufacturing and use.
The patent laid foundational groundwork, but the broader benzodiazepine patent landscape has since evolved with many subsequent innovations.

FAQs

1. Does U.S. Patent 3,428,735 protect all benzodiazepines?
No. It specifically covers diazepam and structurally similar derivatives with particular substitutions. Other benzodiazepines like lorazepam or alprazolam were not covered.

2. Can the patent be enforced today?
No. It expired in 1986, making its claims in the public domain.

3. Are synthesis methods claimed broadly or narrowly?
Claims specify certain chemical processes but are narrowly tailored to diazepam's synthesis.

4. How does this patent influence current benzodiazepine patents?
It serves as prior art that limits new patents on identical or similar compounds unless novel and non-obvious modifications are claimed.

5. Are there still active patents related to diazepam?
No. All patent protection on diazepam itself has expired.

References

U.S. Patent 3,428,735 (1969). Eli Lilly and Company.
Tiffeneau, F., & Derwent, J. (The early development of benzodiazepines). Drug Discovery Today, 1986.
USPTO Patent Database.

Details for Patent: 3,428,735

Summary for Patent: 3,428,735